These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7406481)

  • 1. Pharmacokinetics of alafosfalin, alone and in combination with cephalexin, in humans.
    Allen JG; Lees LJ
    Antimicrob Agents Chemother; 1980 Jun; 17(6):973-9. PubMed ID: 7406481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphonopeptides as antibacterial agents: metabolism and pharmacokinetics of alafosfalin in animals and humans.
    Allen JG; Havas L; Leicht E; Lenox-Smith I; Nisbet LJ
    Antimicrob Agents Chemother; 1979 Sep; 16(3):306-13. PubMed ID: 116591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of food on the bioavailability of alafosfalin, a new antibacterial agent.
    Welling PG; Kendall MJ; Dean S; Wise R; Andrews JM
    J Antimicrob Chemother; 1980 May; 6(3):373-9. PubMed ID: 6893196
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibacterial properties of alafosfalin combined with cephalexin.
    Atherton FR; Hall MJ; Hassall CH; Holmes SW; Lambert RW; Lloyd WJ; Nisbet LJ; Ringrose PS; Westmacott D
    Antimicrob Agents Chemother; 1981 Oct; 20(4):470-6. PubMed ID: 7044291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alafosfalin, a new inhibitor of cell wall biosynthesis: in vitro activity against urinary isolates in Japan and potentiation with beta-lactams.
    Maruyama HB; Arisawa M; Sawada T
    Antimicrob Agents Chemother; 1979 Oct; 16(4):444-51. PubMed ID: 518073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic comparison of cefroxadin (CGP 9000) and cephalexin by simultaneous administration to humans.
    Lecaillon JB; Hirtz JL; Schoeller JP; Humbert G; Vischer W
    Antimicrob Agents Chemother; 1980 Nov; 18(5):656-60. PubMed ID: 7447423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transport of the phosphonodipeptide alafosfalin by the H+/peptide cotransporters PEPT1 and PEPT2 in intestinal and renal epithelial cells.
    Neumann J; Bruch M; Gebauer S; Brandsch M
    Eur J Biochem; 2004 May; 271(10):2012-7. PubMed ID: 15128310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphonopeptide antibacterial agents related to alafosfalin: design, synthesis, and structure-activity relationships.
    Atherton FR; Hall MJ; Hassall CH; Holmes SW; Lambert RW; Lloyd WJ; Ringrose PS
    Antimicrob Agents Chemother; 1980 Dec; 18(6):897-905. PubMed ID: 7016027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic comparison of cephalexin and cefadroxil using HPLC assay procedures.
    Welling PG; Selen A; Pearson JG; Kwok F; Rogge MC; Ifan A; Marrero D; Craig WA; Johnson CA
    Biopharm Drug Dispos; 1985; 6(2):147-57. PubMed ID: 4005394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of dose on the pharmacokinetics of cefadroxil.
    Mariño EL; Dominguez-Gil A
    Eur J Clin Pharmacol; 1980 Nov; 18(6):505-9. PubMed ID: 7461017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of the oral cephalosporins cefaclor, cephradine and cephalexin.
    Welling PG; Dean S; Selen A; Kendall MJ; Wise R
    Int J Clin Pharmacol Biopharm; 1979 Sep; 17(9):397-400. PubMed ID: 500261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics of cephalexin and cephradine in surgical patients].
    Iakovlev VP; Marshak AM; Klimova VS; Lur'e LA
    Antibiotiki; 1977 Aug; 22(8):739-42. PubMed ID: 334053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cefaclor and cephalexin: dosage nomograms for impaired renal function.
    Spyker DA; Thomas BL; Sande MA; Bolton WK
    Antimicrob Agents Chemother; 1978 Aug; 14(2):172-7. PubMed ID: 697345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefetamet pivoxil clinical pharmacokinetics.
    Blouin RA; Stoeckel K
    Clin Pharmacokinet; 1993 Sep; 25(3):172-88. PubMed ID: 8222459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro potentiation of cephalosporins by alafosfalin against urinary tract bacteria.
    Arisawa M; Ohshima J; Ohsawa E; Maruyama HB
    Antimicrob Agents Chemother; 1982 May; 21(5):706-10. PubMed ID: 7103452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of a peptidyl prodrug, alafosfalin, against anaerobic bacteria.
    Grappel SF; Giovenella AJ; Nisbet LJ
    Antimicrob Agents Chemother; 1985 Jun; 27(6):961-3. PubMed ID: 4026269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cephalexin pharmacokinetics].
    Koroleva VG; Vasil'ev VK; Danilova VI; Firsov AA
    Antibiotiki; 1981 Mar; 26(3):113-6. PubMed ID: 7235651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacology of cephalexin.
    Griffith RS
    Postgrad Med J; 1983; 59 Suppl 5():16-27. PubMed ID: 6364086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cephalexin pharmacokinetics in patients with cystic fibrosis.
    Nahata MC; Lubin AH; Visconti JA
    Dev Pharmacol Ther; 1984; 7(4):221-8. PubMed ID: 6468223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penetration of alafosfalin and ampicillin into tissue cage fluid in rabbits.
    Henning C; Cars O
    Chemotherapy; 1982; 28(3):185-8. PubMed ID: 7094659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.